Ipsen's MDM2 Bet: Navtemadlin's Unproven Add-On Strategy Faces High Comparator Bar With No Phase 3 Data

Ipsen Completes Kartos Therapeutics Acquisition, Adds Navtemadlin

Ipsen announced the completion of its acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. This strategic move significantly strengthens Ipsen's late-stage Oncology pipeline by adding navtemadlin, an investigational oral MDM2 inhibitor. Navtemadlin is currently in Phase III clinical development for myelofibrosis, specifically targeting patients who exhibit a suboptimal response to ruxolitinib, the current standard of care. The ongoing Phase III POIESIS study aims to evaluate whether the addition of navtemadlin can improve clinical outcomes compared to ruxolitinib alone in this patient population. Early clinical data suggest navtemadlin has the potential to transform suboptimal responses into clinically meaningful ones, offering enhanced outcomes and potential disease-modifying benefits for intermediate and high-risk TP53wt myelofibrosis patients.

• Ipsen has successfully completed the acquisition of Kartos Therapeutics, a pivotal move that significantly bolsters its late-stage oncology pipeline. This strategic integration brings navtemadlin, an investigational oral MDM2 inhibitor, into Ipsen's portfolio. The acquisition underscores Ipsen's commitment to expanding its presence in oncology and addressing unmet needs, particularly in challenging conditions like myelofibrosis, by leveraging external innovation to accelerate the development of transformative medicines.
• Navtemadlin is positioned as a crucial add-on therapy for patients with myelofibrosis who demonstrate a suboptimal response to ruxolitinib, the current first-line standard of care. This investigational MDM2 inhibitor is undergoing Phase III clinical development in the POIESIS study, which is designed to assess its efficacy in improving clinical outcomes when combined with ruxolitinib. The drug aims to address a significant unmet need, as a large proportion of patients discontinue ruxolitinib treatment due to insufficient response.
• Early clinical data for navtemadlin indicate its potential to transform suboptimal responses to ruxolitinib into clinically meaningful benefits for patients with intermediate and high-risk TP53wt myelofibrosis. This suggests the possibility of achieving both enhanced clinical outcomes and a disease-modifying benefit. Myelofibrosis is a severe condition affecting approximately 1.5 per 100,000 people in the U.S. and Europe, with a high symptom burden and risk of progression to acute myeloid leukemia, highlighting the urgent need for more effective treatment strategies.

Addressing Key Limitations in Myelofibrosis Treatment

Current treatment approaches for myelofibrosis are constrained by a combination of limited efficacy, disease-related complications, and a near-absent curative landscape for the majority of patients. JAK inhibitors, while meaningful in managing splenomegaly and symptom burden, fall short of addressing the underlying disease biology in most patients.

• Lack of disease modification with JAK inhibitors: Despite producing clinically relevant reductions in spleen volume and symptom burden, JAK2 inhibitors such as ruxolitinib and fedratinib do not meaningfully impact disease progression. They have limited capacity to improve bone marrow fibrosis, induce molecular responses, or address cytopenias — underscoring a fundamental gap between symptomatic control and true disease modification.

• Restricted eligibility due to cytopenias: A substantial proportion of patients are ineligible for approved JAK2 inhibitors because of disease-related cytopenias, which are frequently exacerbated by these agents. Neither ruxolitinib nor fedratinib is recommended in patients with severe thrombocytopenia (platelets <50 × 10⁹/L), a subgroup that already carries a particularly poor prognosis. Anemia management in this setting remains a major unmet need.

• Low and variable response rates: Ruxolitinib and fedratinib achieve spleen response rates of only 30%–40%, with high rates of treatment discontinuation over time. At three years, over 40% of patients had discontinued ruxolitinib, with a median drug exposure of 17.5 months in some cohorts.

• Poor outcomes following treatment discontinuation or failure: Post-ruxolitinib outcomes are dismal, with a median survival of 13.2 months following discontinuation. Cessation of therapy also results in rapid return of symptoms to baseline, making dose optimization critical — yet cytopenias remain the most common driver of dose reduction or interruption, directly impinging on the survival benefit associated with adequate dosing.

• Severely limited curative options: Allogeneic hematopoietic stem cell transplantation remains the only potentially curative intervention, but its applicability is restricted by significant transplant-related toxicity, rendering it unavailable to the majority of patients. For those progressing to accelerated or blast phase — an infrequent but profoundly adverse outcome — prognosis is extremely poor, and agents with alternative mechanisms of action are critically needed.

Navtemadlin: A Novel Approach for Myelofibrosis

Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of myelofibrosis (MF) standard-of-care, alongside three additional FDA-approved JAK inhibitors. While these agents reduce symptom burden and spleen volume, they do not alter the natural disease course or mitigate the risk of leukemic transformation, and progressive disease or treatment-related toxicities frequently necessitate discontinuation. Against this backdrop, a meta-analysis of 19 studies encompassing 1,088 patients evaluated 13 distinct ruxolitinib-based combination regimens, revealing meaningfully higher response rates compared to JAK inhibitor monotherapy. Among JAK inhibitor-naïve patients, the combination of ruxolitinib with selinexor demonstrated the highest efficacy (SVR35: 92%; TSS50: 78%), followed by ruxolitinib plus BMS-986158 (SVR35: 90%). Pelabresib, a BET inhibitor, in combination with ruxolitinib also showed durable improvements in spleen volume reduction (SVR35) and total symptom score reduction (TSS50) in the phase 2 MANIFEST study, with an unanchored matching-adjusted indirect comparison versus JAK inhibitor monotherapy trials (COMFORT-I, COMFORT-II, SIMPLIFY-1, JAKARTA) demonstrating response rate ratios consistently greater than 1 for both SVR35 and TSS50 at week 24, with symptom improvements emerging as early as week 12.

Novel JAK inhibitor jaktinib was evaluated in a phase 2 trial of 118 patients, with SVR35 achieved in 54.8% of patients receiving 100 mg BID and 31.3% receiving 200 mg QD at week 24; TSS50 rates were 69.6% and 57.5%, respectively. Notably, jaktinib increased hemoglobin by ≥20 g/L in 35.6% of patients with baseline hemoglobin ≤100 g/L, addressing the clinically significant challenge of MF-related anemia. An indirect treatment comparison of momelotinib versus fedratinib further highlighted safety differentiation, with momelotinib associated with lower risk of any-grade and grade 3/4 anemia, diarrhea, nausea, and dose reduction-leading adverse events in both JAK inhibitor-naïve and -experienced populations, along with significantly reduced thrombocytopenia risk in naïve patients.

In the relapsed/refractory setting, investigational monotherapy approaches have shown more modest results. ABBV-744, a novel BET inhibitor, achieved SVR35 in 24% of patients at week 12 and 33% at week 24 in a phase 1b study of 21 heavily pre-treated patients, with TSS50 rates of 29% and 19% at the respective timepoints. Panobinostat, a pan-deacetylase inhibitor, demonstrated poor tolerability in this population — only 16 of 35 patients completed at least two cycles, with a single patient (3%) achieving an IWG-MRT response. For patients with prior JAK inhibitor exposure, combination strategies continue to show promise; ruxolitinib plus siremadlin, an MDM2 inhibitor, yielded an SVR35 of 45% in this challenging population, underscoring the potential of mechanism-diverse combinations to extend meaningful disease control beyond JAK inhibitor monotherapy.

Navtemadlin: Reshaping Myelofibrosis Treatment for Suboptimal Responders

The acquisition of Kartos Therapeutics by Ipsen, centered on the investigational MDM2 inhibitor navtemadlin, signals a strategic pivot towards addressing critical unmet needs in myelofibrosis (MF). While ruxolitinib has revolutionized MF treatment by improving symptoms and reducing spleen size, a significant challenge remains: many patients experience suboptimal responses or eventually lose efficacy, leading to poor prognoses. Navtemadlin, by restoring p53 activity, offers a novel approach to target the underlying biology of MF, moving beyond symptomatic relief towards potential disease modification.

The ongoing POIESIS Phase III study is particularly noteworthy, evaluating navtemadlin as an add-on to ruxolitinib for patients with suboptimal responses. This strategy aims to enhance the depth and duration of response, potentially improving long-term outcomes like overall survival and progression-free survival, which are increasingly recognized as crucial endpoints in MF. This positions navtemadlin to carve out a significant niche by improving the efficacy of existing therapy rather than solely competing in the second-line monotherapy space.

However, the path forward is not without its complexities.

• MDM2 inhibitors, as a class, have shown hematologic toxicities, including thrombocytopenia and neutropenia, which will require careful management, particularly in a patient population already susceptible to cytopenias.

• The MF therapeutic landscape is becoming increasingly crowded, with a diverse array of novel agents and combination strategies in advanced development. Navtemadlin will need to clearly demonstrate superior benefits to stand out.

• Ultimately, the success of navtemadlin will hinge on its ability to deliver on its promise of disease modification and improved survival, moving beyond the established endpoints of spleen and symptom reduction. If successful, this could represent a significant advancement for patients struggling with the limitations of current treatments.